» Articles » PMID: 35243403

Cutaneous Findings in Myotonic Dystrophy

Overview
Journal JAAD Int
Specialty Dermatology
Date 2022 Mar 4
PMID 35243403
Authors
Affiliations
Soon will be listed here.
Abstract

Myotonic dystrophy types 1 and 2 are a group of complex genetic disorders resulting from the expansion of (CTG) nucleotide repeats in the gene. In addition to the hallmark manifestations of myotonia and skeletal muscle atrophy, myotonic dystrophy also affects a myriad of other organs including the heart, lungs, as well as the skin. The most common cutaneous manifestations of myotonic dystrophy are early male frontal alopecia and adult-onset pilomatricomas. Myotonic dystrophy also increases the risk of developing malignant skin diseases such as basal cell carcinoma and melanoma. To aid in the diagnosis and treatment of myotonic dystrophy related skin conditions, it is important for the dermatologist to become cognizant of the common and rare cutaneous manifestations of this genetic disorder. We performed a PubMed search using the key terms "myotonic dystrophy" AND "cutaneous" OR "skin" OR "dermatologic" AND "manifestation" OR "finding." The resulting publications were manually reviewed for additional relevant publications, and subsequent additional searches were performed as needed, especially regarding the molecular mechanisms of pathogenesis. In this review, we aim to provide an overview of myotonic dystrophy types 1 and 2 and summarize their cutaneous manifestations as well as potential mechanisms of pathogenesis.

References
1.
Wang Y, Pfeiffer R, Alsaggaf R, Meeraus W, Gage J, Anderson L . Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the U.K. Clinical Practice Research Datalink. Int J Cancer. 2017; 142(6):1174-1181. PMC: 5773358. DOI: 10.1002/ijc.31143. View

2.
Mueller C, Hilbert J, Martens W, Thornton C, Moxley 3rd R, Greene M . Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control. 2009; 20(10):2009-20. PMC: 3110730. DOI: 10.1007/s10552-009-9395-y. View

3.
Feng J, LaChance A, Sinclair D, Asgari M . Multiple basal cell carcinomas in a patient with myotonic dystrophy type 1. BMJ Case Rep. 2019; 12(3). PMC: 6441996. DOI: 10.1136/bcr-2018-227233. View

4.
Jones K, Wei C, Iakova P, Bugiardini E, Schneider-Gold C, Meola G . GSK3β mediates muscle pathology in myotonic dystrophy. J Clin Invest. 2012; 122(12):4461-72. PMC: 3533547. DOI: 10.1172/JCI64081. View

5.
Alsaggaf R, Wang Y, Marini-Bettolo C, Wood L, Nikolenko N, Lochmuller H . Benign and malignant tumors in the UK myotonic dystrophy patient registry. Muscle Nerve. 2017; 57(2):316-320. PMC: 7188193. DOI: 10.1002/mus.25736. View